Professor Martin Delatycki is a co-director of the Bruce Lefroy Centre at the Murdoch Children's Research Institute (MCRI) and a clinical geneticist at the Victorian Clinical Genetics Services (VCGS). Martin studied medicine at the University of Melbourne and trained in paediatrics at The Royal Children’s Hospital (RCH).
Martin subsequently trained in Clinical Genetics at VCGS and then obtained his PhD for work on Friedreich ataxia through the MCRI. His research and clinical interests are neurogenetics and community genetics. Martin has over 250 publications and has obtained over $5 million in research funding.
Professor Martin Delatycki is a co-director of the Bruce Lefroy Centre at the Murdoch Children's Research Institute (MCRI) and a clinical geneticist at the Victorian Clinical Genetics Services (VCGS). Martin studied medicine at the University of...
Professor Martin Delatycki is a co-director of the Bruce Lefroy Centre at the Murdoch Children's Research Institute (MCRI) and a clinical geneticist at the Victorian Clinical Genetics Services (VCGS). Martin studied medicine at the University of Melbourne and trained in paediatrics at The Royal Children’s Hospital (RCH).
Martin subsequently trained in Clinical Genetics at VCGS and then obtained his PhD for work on Friedreich ataxia through the MCRI. His research and clinical interests are neurogenetics and community genetics. Martin has over 250 publications and has obtained over $5 million in research funding.
Top Publications
Vogel, AP, Maruff, P, Reece, H, Carter, H, Tai, G, Schultz, BG, Corben, L, Delatycki, MB, Tsanas, A.
Clinically meaningful metrics of speech in neurodegenerative disease: Quantification of speech intelligibility and naturalness in ataxia.
2024
view publication
Lynch, DR, Goldsberry, A, Rummey, C, Farmer, J, Boesch, S, Delatycki, MB, Giunti, P, Hoyle, JC, Mariotti, C, Mathews, KD, et al.
Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data..
Ann Clin Transl Neurol
11(1)
:
4 -16
2024
view publication
Cortese, A, Beecroft, SJ, Facchini, S, Curro, R, Cabrera-Serrano, M, Stevanovski, I, Chintalaphani, S, Gamaarachchi, H, Weisburd, B, Folland, C, et al.
A CCG expansion in ABCD3 causes oculopharyngodistal myopathy in individuals of European ancestry.
2024
view publication
Rius, R, Compton, AG, Baker, NL, Balasubramaniam, S, Best, S, Bhattacharya, K, Boggs, K, Boughtwood, T, Braithwaite, J, Bratkovic, D, et al.
The Australian Genomics Mitochondrial Flagship: A National Program Delivering Mitochondrial Diagnoses.
2024
view publication
Woodcock, IR, Tachas, G, Desem, N, Houweling, PJ, Kean, M, Emmanuel, J, Kennedy, R, Carroll, K, de Valle, K, Adams, J, et al.
A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice..
PLoS One
19(1)
:
e0294847
2024
view publication